Parameters of hemodynamics in patients with chronic obstructive pulmonary disease, measured by oscillometry
Abstract. Heart and pulmonary diseases have common risk factors and pathological processes that contribute to progressive impairment of respiratory function and hemodynamics. Therefore, early detection of the risk factors of cardiovascular diseases (CVD) development in patients with chronic obstructive pulmonary disease (COPD) is essential. The aim: to study hemodynamic parameters using volumetric compression oscillometry in patients with COPD. Material and methods. The study included 133 subjects aged 40 to 64 years (mean age 56 [52; 60] years). Study group consisted of 109 patients with COPD, and the control group consisted of 24 apparently healthy individuals. The study groups were comparable for gender (p = 0.341), age (p = 0.055), and smoking status. Hemodynamic parameters were assessed using volumetric compression oscillometry by means of the APCO-8-RIC-M device. Results. Patients with COPD, comparatively with the control group, had higher cardiac output (5.25 [4.0; 5.6] vs. 4.3 [4.4:4.5] L/min, p = 0.002) and lower total peripheral vascular resistance (1392 [1243; 1671] vs. 1729 [1637; 1735] dyn × s × cm-5, p = 0.002). An analysis of hemodynamic parameters depending on the severity of COPD also revealed that higher disease severity was associated with higher cardiac output, cardiac index, stroke volume, and stroke index (in all cases, p <0.001). Conclusion. As measured by volumetric compression oscillometry, the presence of COPD in a patient affects cardiac output and total peripheral vascular resistance. With increasing COPD severity, hemodynamic parameters measured by volumetric compression oscillometry are getting to be worse.Zh.K. Kanatbekova, A.V. Shakhanov, O.M. Uryasyev, A.A. Nikiforov
Keywords
chronic obstructive pulmonary disease
arterial hypertension
hemodynamic parameters
oscillometry
References
1. Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E et al.; Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015;5(2):020415.
PMID: 26755942. PMCID: PMC4693508. https://doi.org/10.7189/jogh.05.020415
2. Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med. 2019;381(13):1257–66.
PMID: 31553837. https://doi.org/10.1056/NEJMra1900500
3. Crisafulli E, Gorgone P, Vagaggini B, Pagani M, Rossi G, Costa F et al. Efficacy of standard rehabilitation in COPD outpatients with comorbidities. Eur Respir J. 2010;36(5):1042–48.
PMID: 20413540. https://doi.org/10.1183/09031936.00203809
4. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–69.
PMID: 18579551. https://doi.org/10.1183/09031936.0001240
5. Baum C, Ojeda FM, Wild PS, Rzayeva N, Zeller T, Sinning CR et al.; Gutenberg Health Study investigators. Subclinical impairment of lung function is related to mild cardiac dysfunction and manifest heart failure in the general population. Int J Cardiol. 2016:218:298–304.
PMID: 27240155. https://doi.org/10.1016/j.ijcard.2016.05.034
6. Lipworth B, Skinner D, Devereux G, Thomas V, Ling Zhi Jie J, Martin J et al. Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease. Heart. 2016;102(23):1909–14.
PMID: 27380949. PMCID: PMC5136686. https://doi.org/10.1136/heartjnl-2016-309458
7. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C et al.; SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): A double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–26.
PMID: 27203508. https://doi.org/10.1016/S0140-6736(16)30069-1
8. Falk JA, Kadiev S, Criner GJ, Scharf SM, Minai OA, Diaz P. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):543–48.
PMID: 18453369. PMCID: PMC2645333. https://doi.org/10.1513/pats.200708-142ET
9. Sin DD, Man SFP. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? Circulation. 2003;107(11):1514–19.
PMID: 12654609. https://doi.org/10.1161/01.cir.0000056767.69054.b3
10. Rosengren A, Wilhelmsen L. Respiratory symptoms and long-term risk of death from cardiovascular disease, cancer and other causes in Swedish men. Int J Epidemiol. 1998;27(6):962–69.
PMID: 10024189. https://doi.org/10.1093/ije/27.6.962
11. Anthonisen NR, Connett JE, Enright PL, Manfreda J; Lung Health Study Research Group. Hospitalizations and mortality in the lung health study. Am J Respir Crit Care Med. 2002;166(3):333–39.
PMID: 12153966. https://doi.org/10.1164/rccm.2110093
12. Урясьев О.М., Никитина И.Н., Шаханов А.В., Никифоров А.А. Комплексная оценка эндотелиальной дисфункции с использованием компрессионной осциллометрии и определением уровня ассиметричного диметил-аргинина у больных бронхиальной астмой. Наука Молодых (Eruditio Juvenium). 2020;8(3):363–369. (Uryasyev OM, Nikitina IN, Shakhanov AV, Nikiforov AA. Comprehensive assessment of endothelial dysfunction using compression oscillometry and determination of the level of asymmetric dimethyl arginine in patients with bronchial asthma. Nauka molodykh (Eruditio Juvenium) = Science of the Young (Eruditio Juvenium). 2020;8(3):363–369 (In Russ.)).
EDN: PFRIIH. https://doi.org/10.23888/HMJ202083363-369
13. Кароли Н.А., Ребров А.П. Хроническая обструктивная болезнь легких и кардиоваскулярная патология. Клиницист. 2007;2(1):13–19. (Karoli NA, Rebrov AP. Chronic obstructive pulmonary disease and cardiovascular pathology. Klinitsist = The Clinician. 2007;2(1):13–19 (In Russ.)). EDN: MBDVWZ.
14. Almagro P, Soler-Cataluna JJ, Huerta A, Gonzalez-Segura D, Cosío BG; CLAVE Study Investigators. Impact of comorbidities in COPD clinical control criteria. The CLAVE study. BMC Pulm. Med. 2024;24(1):6.
MID: 38166965. PMCID: PMC10759491. https://doi.org/10.1186/s12890-023-02758-0
15. Stone IS, Barnes NC, James WY, Midwinter D, Boubertakh R, Follows R et al. Lung deflation and cardiovascular structure and function in chronic obstructive pulmonary disease. A randomized controlled trial. Am J Respir Crit Care Med. 2016;193(7):717–26.
PMID: 26550687. PMCID: PMC5440091. https://doi.org/10.1164/rccm.201508-1647OC
16. Andre S, Conde B, Fragoso E, Boleo-Tome JP, Areias V, Cardoso J; GI DPOC-Grupo de Interesse na Doença Pulmonar Obstrutiva Crónica. COPD and cardiovascular disease. Pulmonology. 2019;25(3):168–76.
PMID: 30527374. https://doi.org/10.1016/j.pulmoe.2018.09.006
About the Authors
Zharkynay K. Kanatbekova, MD, postgraduate student of the Department of faculty therapy named after professor V.Y. Garmash, Academician I.P. Pavlov Ryazan State Medical University, Ryazan, Russian Federation.E-mail: janya_kanatbekova@mail.ru
ORCID: https://orcid.org/0000-0003-3314-760X
Anton V. Shakhanov, MD, PhD (Medicine), associate professor, associate professor of the Department of faculty therapy named after professor V.Ya. Garmash, Academician I.P. Pavlov Ryazan State Medical University, Ryazan, Russian Federation.
E-mail: shakhanovav@gmail.com
ORCID: https://orcid.org/0000-0002-5706-9418
Oleg M. Uryasyev, MD, Dr. Sci. (Medicine), professor, head of the Department of faculty therapy named after professor V.Ya. Garmash, Academician I.P. Pavlov Ryazan State Medical University, Ryazan, Russian Federation.
E-mail: uryasev08@yandex.ru
ORCID: https://orcid.org/0000-0001-8693-4696
Alexander A. Nikiforov, MD, PhD (Medicine), associate professor, head of the Central research laboratory, Academician I.P. Pavlov Ryazan State Medical University, Ryazan, Russian Federation.
E-mail: a.nikiforov@rzgmu.ru
ORCID: https://orcid.org/0000-0002-7364-7687
Similar Articles
